Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine

PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the combination of weekly oxaliplatin × 4, weekly irinotecan × 4 and capecitabine Monday through Friday for 4 weeks of every 6 week cycle in patients with solid tumors; to determine the pharmacokinetic profile...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Krishnamurthi, Smitha S., Brell, Joanna M., Hoppel, Charles L., Egorin, Merrill J., Weaver, Karen C., Li, Xiaolin, Ingalls, Stephen T., Zuhowski, Eleanor G., Schluchter, Mark D., Dowlati, Afshin, Cooney, Matthew M., Gibbons, Joseph, Overmoyer, Beth A., Ivy, S. Percy, Remick, Scot C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4788493/
https://ncbi.nlm.nih.gov/pubmed/18414865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0754-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados